All news

News

Lilly’s GLP-1 pill Foundayo treats sleep apnea — how oral options change the math for telehealth buyers

Eli Lilly's oral GLP-1 Foundayo successfully treats sleep apnea in late-stage trials, offering a needle-free but slightly less potent alternative to Zepbound.

By CompareRx Editorial Team · Medically reviewed by CompareRx Medical Review Desk
Published
A close-up of a daily oral medication pill next to a sleep apnea mask, representing needle-free GLP-1 therapy.

Key takeaways

  • Eli Lilly's experimental oral GLP-1 pill, Foundayo, successfully reduced sleep apnea events in two late-stage clinical trials.
  • Placebo performance: By comparison, those in the placebo group saw a reduction of only 4.5 events per hour.
  • Disease severity: Approximately 28% of patients treated with Foundayo achieved disease remission or transitioned to mild disease status, compared to just 13% of the placebo group.

Compare providers side by side or read the full GLP-1 guides.

Key takeaways

  • Eli Lilly's experimental oral GLP-1 pill, Foundayo, successfully reduced sleep apnea events in two late-stage clinical trials.

What happened

In late-stage clinical trial results presented at the annual meeting of the American Heart Association and published in JAMA, Eli Lilly announced that its experimental oral GLP-1 pill, Foundayo, successfully alleviated obstructive sleep apnea. However, while the needle-free pill demonstrated significant clinical benefits, the data indicates it may not be quite as powerful as Lilly’s existing injectable weight-loss therapy, Zepbound.

Why it matters

Obstructive sleep apnea (OSA) is highly correlated with obesity, and treating it historically required cumbersome continuous positive airway pressure (PAP) machines. The emergence of a daily oral medication that treats OSA while simultaneously promoting weight loss could revolutionize care for patients who dislike needles.

For online telehealth buyers, this development introduces a critical choice: the convenience of a daily pill versus the superior clinical efficacy of a weekly injection. Because oral GLP-1s are easier to manufacture at scale than complex auto-injector pens, the eventual launch of Foundayo could ease the persistent supply shortages that plague the telehealth market and offer a more affordable, insurance-friendly alternative.

What the data says

The data presented by Eli Lilly evaluated patients suffering from obstructive sleep apnea who were not receiving PAP therapy over a one-year period.

  • Apnea reduction: Patients taking oral Foundayo experienced an average reduction of 17.8 "events" per hour on the apnea-hypopnea index (AHI), which measures how frequently breathing stops or becomes restricted during sleep.
  • Placebo performance: By comparison, those in the placebo group saw a reduction of only 4.5 events per hour.
  • Disease severity: Approximately 28% of patients treated with Foundayo achieved disease remission or transitioned to mild disease status, compared to just 13% of the placebo group.

Despite these strong numbers, the trial data indicates Foundayo is less effective at treating sleep apnea than Lilly's injectable dual GLP-1/GIP drug, Zepbound (tirzepatide), which has previously shown even greater reductions in AHI events.

How it compares

The prospect of an oral GLP-1 introduces a major structural shift for consumers comparing treatment options. Currently, the online GLP-1 market is dominated by injectable semaglutide and tirzepatide, which patients can access through various providers or compare directly using our interactive questionnaire.

Injectables generally offer superior weight-loss and therapeutic outcomes. However, they require weekly self-injections and sterile handling. A pill like Foundayo offers several distinct advantages for cash-paying buyers:

  • No needle phobia: Oral administration bypasses the anxiety of self-injection.
  • No cold-chain shipping: Injectables require refrigerated shipping and storage, which drives up logistics fees. A tablet can be shipped and stored at room temperature.
  • Reduced manufacturing bottlenecks: Pill manufacturing does not rely on the specialized syringe-filling facilities that have historically caused severe GLP-1 shortages.

However, patients will have to weigh these logistical benefits against the drug's lower clinical potency compared to injectables.

How this fits the bigger picture

This study adds to a rapidly expanding body of research exploring how next-generation obesity treatments address complex comorbidities beyond simple weight loss. We have previously covered how these dual-action drugs provide profound secondary health benefits, such as how Lilly's upcoming triple-agonist retatrutide targets joint health, detailed in our report on how Lilly’s retatrutide cuts knee arthritis pain.

Furthermore, the American Heart Association presentation of the Foundayo data coincides with anticipation around other oral obesity pipelines. For a deeper look at competitive oral clinical trials, see our analysis on what orforglipron sleep apnea results mean for GLP-1 buyers.

For US consumers who pay out-of-pocket, the arrival of oral medications will likely disrupt the pricing models of major telehealth platforms. Platforms that currently charge $200 to $400 per month for compounded injectables may soon find themselves competing with highly stable, mass-produced oral options that are much cheaper to distribute.

What happens next

The data published in JAMA represents a significant milestone, but Foundayo is not yet approved by the FDA for obstructive sleep apnea or weight loss. Eli Lilly is expected to continue submitting these late-stage trial results to regulatory authorities to secure marketing approval.

As these clinical trials progress, US buyers will continue to rely on existing FDA-approved injectables and compounded alternatives. Patients interested in starting their medical weight-loss journey can explore our comprehensive directory of the cheapest telehealth GLP-1 options currently available on the market.

Disclaimer: CompareRx does not provide medical advice. Always consult a licensed healthcare provider before starting or changing any medication regimen.

Find the provider that fits your budget

Compare 100+ online GLP-1 providers on true monthly cost, or get your top 3 matches in 90 seconds.

More from the newsroom

Popular comparisons

Sources

Community

What do you make of this?

Add your take, ask a question, or tell us what you're seeing with your own provider — our editors read every thread.

Medical disclaimer: CompareRx.org is an independent comparison site and publisher. This article is informational only, is not medical advice, and is not a substitute for care from a licensed clinician. Read our medical disclaimer, editorial policy and affiliate disclosure.